BIORCHESTRA is focused on advancing the field of nanomedicine through its proprietary BDDS™ (Biomolecule Delivery and Diagnostic System) platform. This innovative technology is designed to enhance the delivery of therapeutic biomolecules, improving their efficacy and reducing potential side effects. By utilizing nanotechnology, BIORCHESTRA aims to create targeted delivery systems that can effectively transport drugs to specific sites within the body, thereby optimizing treatment outcomes for various diseases.

In addition to its BDDS™ platform, BIORCHESTRA emphasizes the importance of its core technologies, which are integral to its research and development efforts. These technologies encompass a range of methodologies aimed at understanding and manipulating biological processes at the molecular level. The company is committed to leveraging these advanced technologies to develop a robust pipeline of therapeutic programs, focusing on areas such as gene therapy and RNA-based treatments, ultimately striving to address unmet medical needs and improve patient care.

South Korea

BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization.

Cancer

Central Nervous System (CNS)

Nervous System Diseases

BIORCHESTRA

Alzheimer's disease

Amyotrophic lateral sclerosis

Parkinson's disease

Bioorch Drug #1

Small Molecule Pharmaceuticals

Epilepsy

Biorch Drug #2

Biologics

Solid tumor/s

Biorch Drug #3

Spinocerebellar Ataxia

Biorch Drug #4

Gene Therapy

NanoMedicine/Nanotechnology

RNA Therapies

Therapeutic

BIORCHESTRA

Company Details